Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

NCT02239146 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02239146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02239146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2005
Completion date
January 31, 2008
Enrollment
43 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, cardiac surgery requiring cardiopulmonary bypass